Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

February 23, 2017 0

Making Sure that CAR-T Therapy for Cancer Succeeds Academic Researchers Identify a New Process to Raise …

Agenus: Why Canceling Prophage Trial Should Not be Concerning

February 22, 2017 0

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore …

Exelixis: Speeding Towards Becoming a Top-Tier Biopharmaceutical

February 21, 2017 0

Watching the outperformance of the new approaches for cancer immunotherapies, especially the checkpoint inhibitors and other …

A Quick Opinion on the CRISPR Patenting Story. Gillead’s Improvement of HIV Treatment

February 17, 2017 0

About the CRISPR/Cas9 Gene Editing Patent Shareholders of biotechnology firms specialized in CRISPR gene editing technology …

Seattle Genetics’ Agreement with Immunomedics: The Benefit Vs. the Risk

February 14, 2017 0

Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to …

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

February 14, 2017 0

Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that …

Interpreting Portola Pharmaceuticals’ News

February 9, 2017 0

The FDA’s Center for Drug Evaluation and Research (CDER) informed Portola (PTLA) that it does not …

Gilead Sciences: A Case Study

February 9, 2017 0

Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the …

Prohost Letter #404 Part 2

February 6, 2017 0

Prohost Letter #404 Part 2 Synthetic Biology (2) A Brief History DNA is the software of …

How Good Is Xoma’s Good News?

February 4, 2017 0

XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Congenital Hyperinsulinism Phase 2 …

Companies Targeted for Takeover Yet Can Thrive on their Own

February 2, 2017 0

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order …

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

January 30, 2017 0

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor …

Prohost Letter #404 Part 1

January 23, 2017 0

Prohost Letter #404 Part 1 HAPPY SPIRITUAL HOLIDAYS HAPPY NEW YEA

Welcoming Jounce Therapeutics (JNCE) as a Public Company

January 22, 2017 0

Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE). The Company, …

While You Were Sleeping

January 17, 2017 0

A few months ago, we heard news that a Belgium firm called Celyad (CYAD) has concluded …

Vertex and Merck KGaA Agreement Suits Both Firms

January 13, 2017 0

Vertex (VRTX) entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development …

Will the FDA Approve Amgen’s Drug Parsabiv Next Month?

January 11, 2017 0

Amgen (AMGN) The Journal of the American Medical Association (JAMA) published findings from three Phase 3 …

Takeda Acquires Ariad for $5.2 Billion

January 9, 2017 0

ARIAD Pharmaceuticals’ (ARIA) stock jumped 75% today. The oncology firm entered into a definitive agreement to be …

Halozyme’s PEGPH20 Trial Results Are Worth Appreciating Not Doubting

January 6, 2017 0

Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center …

Some More Important News that Precedes the Upcoming Prohost Letter

January 5, 2017 0

GILEAD (GILD) One analyst who aimed at bringing only the negatives about biotech has finally succeeded …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Academic Researchers Improve on CAR-T Immunotherapy. Guess Who the Beneficiaries Are?

Agenus: Why Canceling Prophage Trial Should Not be Concerning

Exelixis: Speeding Towards Becoming a Top-Tier Biopharmaceutical

A Quick Opinion on the CRISPR Patenting Story. Gillead’s Improvement of HIV Treatment

Seattle Genetics’ Agreement with Immunomedics: The Benefit Vs. the Risk

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

Interpreting Portola Pharmaceuticals’ News

Gilead Sciences: A Case Study

Prohost Letter #404 Part 2

How Good Is Xoma’s Good News?

Companies Targeted for Takeover Yet Can Thrive on their Own

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

Prohost Letter #404 Part 1

Welcoming Jounce Therapeutics (JNCE) as a Public Company

While You Were Sleeping

Vertex and Merck KGaA Agreement Suits Both Firms

Will the FDA Approve Amgen’s Drug Parsabiv Next Month?

Takeda Acquires Ariad for $5.2 Billion

Halozyme’s PEGPH20 Trial Results Are Worth Appreciating Not Doubting

Some More Important News that Precedes the Upcoming Prohost Letter